TY - JOUR
T1 - Measuring the symptom burden of lung cancer
T2 - The validity and utility of the lung cancer module of the M. D. Anderson symptom inventory
AU - Mendoza, Tito R.
AU - Shelleywang, Xin
AU - Lu, Charles
AU - Palos, Guadalupe R.
AU - Liao, Zhongxing
AU - Mobley, Gary M.
AU - Kapoor, Shitij
AU - Cleeland, Charles S.
PY - 2011
Y1 - 2011
N2 - We conducted a study to establish the psychometric properties of a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with lung cancer (MDASI-LC). The MDASI measures 13 common "core" symptoms of cancer and its treatment. The MDASI-LC includes the 13 core MDASI symptom items and three lung cancer-specific items: coughing, constipation, and sore throat. MDASI-LC items were administered to three cohorts of patients with lung cancer undergoing either chemotherapy or chemoradiotherapy. Known-group validity and criterion (concurrent) validity of the MDASI-LC were evaluated using the Eastern Cooperative Oncology Group performance status and the 12-item Short- Form Health Survey. The internal consistency and test-retest reliability of the module were adequate, with Cronbach coefficient _-values of 0.83 or higher for all module items and subscales. The sensitivity of the MDASI-LC to changes in patient performance status (disease progression) and to continuing cancer treatment (effects of treatment) was established. Cognitive debriefing of a subset of participants provided evidence for content validity and indicated that the MDASI core items and three additional lung cancer- specific items were clear, relevant to patients, and easy to understand; only two patients suggested additional symptom items. As expected, the item "sore throat" was sensitive only for patients receiving chemoradiotherapy. The MDASI-LC is a valid, reliable, and sensitive symptom-assessment instrument whose use can enhance clinical studies of symptom status in patients with lung cancer and epidemiological and prevalence studies of symptom severity across various cancer types.
AB - We conducted a study to establish the psychometric properties of a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with lung cancer (MDASI-LC). The MDASI measures 13 common "core" symptoms of cancer and its treatment. The MDASI-LC includes the 13 core MDASI symptom items and three lung cancer-specific items: coughing, constipation, and sore throat. MDASI-LC items were administered to three cohorts of patients with lung cancer undergoing either chemotherapy or chemoradiotherapy. Known-group validity and criterion (concurrent) validity of the MDASI-LC were evaluated using the Eastern Cooperative Oncology Group performance status and the 12-item Short- Form Health Survey. The internal consistency and test-retest reliability of the module were adequate, with Cronbach coefficient _-values of 0.83 or higher for all module items and subscales. The sensitivity of the MDASI-LC to changes in patient performance status (disease progression) and to continuing cancer treatment (effects of treatment) was established. Cognitive debriefing of a subset of participants provided evidence for content validity and indicated that the MDASI core items and three additional lung cancer- specific items were clear, relevant to patients, and easy to understand; only two patients suggested additional symptom items. As expected, the item "sore throat" was sensitive only for patients receiving chemoradiotherapy. The MDASI-LC is a valid, reliable, and sensitive symptom-assessment instrument whose use can enhance clinical studies of symptom status in patients with lung cancer and epidemiological and prevalence studies of symptom severity across various cancer types.
KW - Symptoms assessment validation lung cancer
UR - http://www.scopus.com/inward/record.url?scp=79952614928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952614928&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2010-0193
DO - 10.1634/theoncologist.2010-0193
M3 - Article
C2 - 21285393
AN - SCOPUS:79952614928
SN - 1083-7159
VL - 16
SP - 217
EP - 227
JO - Oncologist
JF - Oncologist
IS - 2
ER -